Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1247228.RAG9JFe5B9OyOYwuVgY19r-I7NDZBfRd_4GEJhXJ0Eqkw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1247228.RAG9JFe5B9OyOYwuVgY19r-I7NDZBfRd_4GEJhXJ0Eqkw130_assertion type Assertion NP1247228.RAG9JFe5B9OyOYwuVgY19r-I7NDZBfRd_4GEJhXJ0Eqkw130_head.
- NP1247228.RAG9JFe5B9OyOYwuVgY19r-I7NDZBfRd_4GEJhXJ0Eqkw130_assertion description "[Using a mouse model of Ph+ ALL that accurately mimics the genetics, clinical behavior, and therapeutic response of the human disease, we show that a combination of 2 agents approved by the US Food and Drug Administration (dasatinib and ruxolitinib, which inhibit BCR-ABL and Janus kinases, respectively), significantly extends survival by targeting parallel signaling pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1247228.RAG9JFe5B9OyOYwuVgY19r-I7NDZBfRd_4GEJhXJ0Eqkw130_provenance.
- NP1247228.RAG9JFe5B9OyOYwuVgY19r-I7NDZBfRd_4GEJhXJ0Eqkw130_assertion evidence source_evidence_literature NP1247228.RAG9JFe5B9OyOYwuVgY19r-I7NDZBfRd_4GEJhXJ0Eqkw130_provenance.
- NP1247228.RAG9JFe5B9OyOYwuVgY19r-I7NDZBfRd_4GEJhXJ0Eqkw130_assertion SIO_000772 25499760 NP1247228.RAG9JFe5B9OyOYwuVgY19r-I7NDZBfRd_4GEJhXJ0Eqkw130_provenance.
- NP1247228.RAG9JFe5B9OyOYwuVgY19r-I7NDZBfRd_4GEJhXJ0Eqkw130_assertion wasDerivedFrom befree-2016 NP1247228.RAG9JFe5B9OyOYwuVgY19r-I7NDZBfRd_4GEJhXJ0Eqkw130_provenance.
- NP1247228.RAG9JFe5B9OyOYwuVgY19r-I7NDZBfRd_4GEJhXJ0Eqkw130_assertion wasGeneratedBy ECO_0000203 NP1247228.RAG9JFe5B9OyOYwuVgY19r-I7NDZBfRd_4GEJhXJ0Eqkw130_provenance.